Want to see GB:PRM full AI Analyst Report?
PRM Stock Chart & Stats
1.58 p
0.33 p(18.56%)
At close: 4:00 PM EDT
1.58 p
0.33 p(18.56%)
Day’s Range― - ―
52-Week Range1.11 p - 4.40 p
Previous CloseN/A
Volume25.52K
Average Volume (3M)123.22K
Market Cap
£4.73M
Enterprise Value20.50M
Total Cash (Recent Filing)£1.10M
Total Debt (Recent Filing)£15.95M
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume73,280
30 Day Avg. Volume123,216
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Fee-for-service Business ModelA fee-for-service model gives Proteome Sciences multiple potential customer groups and ties revenue to outsourced research activity. Its work supports drug discovery and biomarker research, areas where specialized external analytical capacity can remain strategically useful over multiple project cycles.
Specialized Proteomics CapabilitiesSpecialized mass-spectrometry and protein-analysis capabilities provide a differentiated technical foundation for biomedical research and drug development services. This expertise can support complex studies and help the company remain relevant to customers needing specialized proteomic datasets and analysis.
Improved Cash-flow TrendAlthough cash generation remains negative, the substantially smaller 2025 free-cash-flow deficit indicates some improvement in cash discipline versus the prior year. If sustained, this could reduce the pace of funding needs and provide a better base for stabilizing operations.
Bears Say
Revenue And Profitability DeteriorationThe simultaneous revenue decline, negative gross profit and widened net loss point to weak cost absorption and limited earnings stability. Persistent operating losses reduce internal funding capacity and make it harder to invest in laboratory capabilities or scale the service business sustainably.
Strained Balance SheetRising debt alongside deeply negative equity leaves Proteome Sciences with limited balance-sheet flexibility. This capital structure can constrain investment, increase dependence on refinancing or external capital, and expose shareholders to dilution risk if additional funding is required.
Weak Self-funding CapacityNegative free cash flow means the business is not yet consistently funding its operations and development internally. Historical volatility further reduces predictability, potentially forcing management to rely on financing or other external support during periods of weaker project activity.
Proteome Sciences News
PRM FAQ
What was Proteome Sciences PLC’s price range in the past 12 months?
Proteome Sciences PLC lowest share price was 1.11 p and its highest was 4.40 p in the past 12 months.
What is Proteome Sciences PLC’s market cap?
Proteome Sciences PLC’s market cap is £4.73M.
When is Proteome Sciences PLC’s upcoming earnings report date?
Proteome Sciences PLC’s upcoming earnings report date is Apr 01, 2027 which is in 160 days.
How were Proteome Sciences PLC’s earnings last quarter?
Proteome Sciences PLC released its earnings results on Jul 23, 2026. The company reported -0.004 p earnings per share for the quarter.
Is Proteome Sciences PLC overvalued?
According to Wall Street analysts Proteome Sciences PLC’s price is currently Overvalued.
Does Proteome Sciences PLC pay dividends?
Proteome Sciences PLC does not currently pay dividends.
What is Proteome Sciences PLC’s EPS estimate?
Proteome Sciences PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Proteome Sciences PLC have?
Proteome Sciences PLC has 350,724,900 shares outstanding.
What happened to Proteome Sciences PLC’s price movement after its last earnings report?
Proteome Sciences PLC reported an EPS of -0.004 p in its last earnings report. Following the earnings report the stock price went up 4.396%.
Which hedge fund is a major shareholder of Proteome Sciences PLC?
Currently, no hedge funds are holding shares in GB:PRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Proteome Sciences PLC
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant that provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator which analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also offers top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, as well as to academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.